Cardio3 BioSciences Ups R&D Efforts After CV Stem Cell Product Clears Safety Review
This article was originally published in Pharmaceutical Approvals Monthly
Belgian regenerative therapies company plans to enlarge its R&D and partnering efforts after a pre-planned interim review by a Data Safety Monitoring Board gave the Phase III study of lead product C-Cure a clean bill of health.
You may also be interested in...
Data from two trials of vagus nerve stimulation to treat heart failure, sponsored by Boston Scientific and Cyberonics, respectively, were not particularly positive for the future of this therapy. But another developer of a VNS system for heart failure, BioControl, says the results won’t affect its chances for approval.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.